Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of TMS-tACS on Central Autonomic Coupling and Cognition

11 de noviembre de 2026 actualizado por: Xidian University

Modulatory Effects of Combined TMS-tACS Stimulation on Central Autonomic Coupling and Cognitive Function

This study investigates the effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling in healthy adults, while exploring the underlying neural mechanisms. Participants will undergo four different neuromodulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of stimulation sessions will be counterbalanced using a randomized Latin square design. During each experimental session, researchers will simultaneously record participants' electroencephalography (EEG), electrocardiography (ECG), respiratory, and gastric signals before and after stimulation, and evaluate cognitive performance through behavioral tasks following stimulation. The primary objective of this study is to investigate how different neuromodulation patterns influence brain-visceral coupling and cognitive function, and to further examine the relationship between changes in central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the neural mechanisms underlying cognitive regulation and optimizing future non-invasive neuromodulation approaches.

Descripción general del estudio

Descripción detallada

This is an exploratory, randomized, single-blind, sham-controlled, within-subject crossover study designed to investigate the regulatory effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling, as well as the underlying neural mechanisms in healthy adults.

Participants will undergo four experimental stimulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of the four stimulation conditions will be balanced using a Latin square design to minimize potential sequence effects, learning effects, and carry-over effects between conditions. A minimum interval of one week will be maintained between experimental sessions. Before stimulation, participants will undergo safety screening and resting motor threshold (RMT) assessment, which will be used to determine individualized stimulation parameters.

During each experimental session, researchers will simultaneously record multimodal physiological signals, including electroencephalography (EEG), electrocardiography (ECG), respiratory signals, and gastric electrical activity, before and after stimulation. Following the intervention, participants will complete cognitive assessment tasks to evaluate changes in cognitive performance induced by different neuromodulation conditions. Participants will not be informed of the specific stimulation condition received in each session to ensure the objectivity and scientific validity of the study.

Primary outcome measures include: brain-visceral coupling metrics, which characterize bidirectional interactions between central neural activity and autonomic physiological rhythms; heartbeat-evoked potentials (HEP), an EEG component time-locked to ECG R-peaks that reflects cortical processing of cardiac afferent information and interoceptive function; heart rate variability (HRV), which reflects autonomic nervous system regulation; and EEG oscillatory activity, which evaluates changes in neural rhythmic dynamics induced by stimulation. Cognitive performance measures will also be collected to investigate the relationship between alterations in brain-visceral coupling and cognitive function.

The primary objective of this study is to systematically examine how different neuromodulation patterns, including TMS, tACS, and combined TMS-tACS stimulation, influence brain-visceral coupling and cognitive function, and to further explore the association between central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the mechanisms of brain-body interaction and optimizing future non-invasive neuromodulation approaches for cognitive enhancement.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 71000
        • Reclutamiento
        • Xidian University
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 55 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  1. Age between 18 and 55 years.
  2. Right-handed individuals.
  3. Body mass index (BMI) between 18 and 24.
  4. No contraindications to transcranial magnetic stimulation (TMS).
  5. No history of clinically significant cardiac disease.
  6. No gastrointestinal disorders.
  7. No respiratory system disorders.
  8. No ear-related diseases.
  9. Voluntary participation and provision of written informed consent.
  10. No participation in other neuromodulation studies within the past month.
  11. Ability to understand the experimental procedures and complete cognitive tasks as required.

Exclusion Criteria

  1. History of epilepsy, traumatic brain injury, severe headache, brain surgery, or other neurological disorders.
  2. History of psychiatric disorders, cognitive impairment, or recent use of medications that may affect central nervous system excitability, including sedatives, antidepressants, or stimulants.
  3. Presence of any contraindications to TMS, including metallic implants, cardiac pacemakers, implantable electronic devices, cochlear implants, or other implanted devices.
  4. Infection, inflammation, ulceration, skin lesions, allergy, reduced sensation, or structural abnormalities of the external ear or stimulation sites.
  5. History of vagus nerve injury or related surgical procedures.
  6. History of cardiovascular diseases, respiratory diseases, gastrointestinal ulcers, or other medical conditions that may affect experimental safety or study outcomes.
  7. Bilateral hand dysfunction preventing completion of experimental tasks.
  8. Current smoking, long-term substance dependence, or recent conditions that may influence study outcomes, such as severe sleep deprivation, alcohol consumption, or excessive fatigue.
  9. Recent participation in other neuromodulation-related experiments.
  10. Refusal to sign the informed consent form.
  11. Any other conditions considered unsuitable for participation by the investigators.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: TMS group

Transcranial Magnetic Stimulation (TMS) Stimulation Condition

Transcranial magnetic stimulation was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site based on the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second inter-train intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. No concurrent tACS stimulation was applied during this condition.

Experimental: tACS group

Transcranial Alternating Current Stimulation (tACS) Stimulation Condition

Transcranial alternating current stimulation (tACS) was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site according to the international 10-20 EEG system. The stimulation intensity was set at 1 mA and continuously delivered for 15 minutes, including 5-second ramp-up and ramp-down periods. No concurrent transcranial magnetic stimulation was applied during this condition.

Experimental: TMS-tACS combined stimulation group

Combined TMS-tACS Stimulation Condition

Combined transcranial magnetic stimulation and transcranial alternating current stimulation (TMS-tACS) were applied to the dorsolateral prefrontal cortex (DLPFC) targeting the F3 site according to the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. Transcranial alternating current stimulation (tACS) was applied simultaneously with an intensity of 1 mA for 15 minutes, including 5-second ramp-up and ramp-down periods. During combined stimulation, TMS pulses were triggered at the peak phase of the tACS sinusoidal waveform to achieve phase-synchronized neuromodulation.

Comparador falso: Sham stimulation group

Sham Stimulation Condition

A sham stimulation condition was applied to simulate the sensory experience of active TMS-tACS stimulation without delivering effective neuromodulation. During sham tACS, electrical current was briefly delivered at the beginning of stimulation to mimic the initial skin sensation, while sham TMS was performed using prerecorded stimulation sounds to reproduce the auditory experience associated with active stimulation. No effective magnetic or electrical stimulation was delivered.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Heart-Brain Coupling (Modulation Index)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrocardiography (ECG) data will be recorded. Heart-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between cardiac rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Modulation Index)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and respiratory signals will be recorded. Respiration-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between respiratory rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Modulation Index)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrogastrography (EGG) data will be recorded. Gastric-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between gastric electrical rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Heart-Brain Coupling (Phase-Locking Value)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between cardiac-related rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Heart-Brain Coupling (Mean Vector Length)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between cardiac-related phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Phase-Locking Value)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between respiratory rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Mean Vector Length)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between respiratory phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Phase-Locking Value)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between gastric electrical rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Mean Vector Length)
Periodo de tiempo: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between gastric electrical phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
N-back Working Memory Task Performance (d-prime)
Periodo de tiempo: After each stimulation session, during the post-stimulation cognitive assessment.

Working memory performance will be assessed using the N-back task. The sensitivity index (d-prime, d') will be calculated based on the hit rate and false alarm rate using signal detection theory. Higher d-prime values indicate better working memory performance and greater ability to discriminate target from non-target stimuli.

After each stimulation session, during the post-stimulation cognitive assessment.
Visuospatial Working Memory Task Accuracy
Periodo de tiempo: After each stimulation session, during the post-stimulation cognitive assessment.

Visuospatial working memory performance will be assessed using a visuospatial memory task. Task accuracy will be calculated as the percentage of correct responses relative to the total number of responses. Accuracy ranges from 0% to 100%, with higher values indicating better visuospatial working memory performance.

After each stimulation session, during the post-stimulation cognitive assessment.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de diciembre de 2026

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

30 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir